T0	Outcomes 152 198	safety, efficacy and imaging pharmacodynamics.
T1	Outcomes 736 740	arm.
T2	Outcomes 741 780	Exploratory pharmacodynamic assessments
T3	Outcomes 859 897	A, plasma AUC and C (max) of cediranib
T4	Outcomes 1030 1063	reduces cediranib plasma exposure
T5	Outcomes 1196 1231	with sustained antivascular effects
T6	Outcomes 1265 1304	reductions in DCE-MRI parameters and CT
T7	Outcomes 1410 1441	Evidence of antitumour activity
T8	Outcomes 1483 1523	effects upon imaging vascular parameters